BETA
Early release — we are building new features fast, you may encounter issues. Help us improve:
contact us
to report bugs or share feedback.
Loading...
Equity Desk
Earnings Calendar
IPO Calendar
Screener
Analyst Consensus
Smart Money
Insider Activity
Short Interest
Analytics
Equity Analytics
←
Back to Equity Analytics
Equity Analytics
/
RGEN
RGEN
Repligen Corporation
Healthcare - US
Repligen Corporation is a global life sciences company specializing in the development and commercialization of bioprocessing technologies and systems designed to increase efficiencies in the manufacturing of biological drugs. Its core prod…
Show more
HQ: Waltham, MA, United States of America
www.repligen.com
USD
167.79
+0.76%
vs prev. close
Overview
Fundamentals
Ownership & Activity
Analyst Consensus
Seasonality & Patterns
News
Research
Performance
1W
-1.16%
1M
-5.07%
3M
-0.58%
1Y
+5.39%
YTD
+1.62%
Valuation
P/E
—
EPS TTM
-0.21
Dividend yield
—
Size and risk
Market cap
$10.6B
Beta
1.12
Price history
RGEN price
USD
Line
Candle
Volume
Total return
Events
Vs index
Log scale
1m
3m
6m
1y
3y
5y
10y
max
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Valuation & performance
Risk
Repligen
RGEN
Medical Instruments & Supplies
Mkt cap (USD bn)
10.6
P/E
—
Div yld
—
1W
-1.2%
1M
-5.1%
3M
-0.6%
6M
+61.1%
1Y
+5.4%
YTD
+1.6%
Company
Ticker
Industry
Mkt cap (USD bn)
P/
E
Div yld
1W
1M
3M
6M
1Y
YTD
Repligen
RGEN
Medical Instruments & Supplies
10.6
—
—
-1.2%
-5.1%
-0.6%
+61.1%
+5.4%
+1.6%
Subscribe to Equity Analytics to compare RGEN with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.
View plans
Ask Ashenden
Ask, then keep asking: it follows the conversation for 30 minutes, grounded in Ashenden research.
Ask
Built on Ashenden research and our own data. Answers are AI-generated: they can be wrong or incomplete — check anything you would act on.
Is RGEN cheap or expensive against its peers, and what justifies the gap?
What does the price already assume about RGEN?
What would have to go wrong for RGEN from here?
Why RGEN now, and not a year ago?